-
2025-522484-15-00
ER+/HER2- early breast cancer 5 2026-04-27
-
2025-521884-12-00
First line triple-negative breast cancer (TNBC) 5 2026-03-19
-
2025-523083-21-00
PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
-
2024-520290-12-00
Hormone receptor–positive (HRpos)/human epidermal growt 6 2025-11-04
-
2024-513852-13-00
KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic 5 2025-01-20
-
2023-509292-17-00
primary high-risk lobular breast cancer 4 2024-11-08
-
2023-508787-29-00
Triple-negative early breast cancer with low risk for r 4 2024-10-10
-
2023-504962-52-00
Triple negative breast cancer. 5 2024-07-10
-
2023-504323-25-01
breast cancer 5 2024-03-19
-
2022-502980-39-00
Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
-
2022-502046-28-00
HER2-Positive, PIK3CA Mutated, Locally Advanced or Meta 5 2023-12-22
-
2023-505928-59-00
Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
-
2024-514458-61-01
HER2+ early breast cancer 4 2024-02-05
-
2022-502322-41-00
Metastatic breast cancer 5 2023-09-12
-
2023-503990-39-00
Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
-
2023-505249-24-00
HER2-positive metastatic breast cancer 5 2021-05-27
-
2023-503995-26-00
Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
-
2023-503568-18-00
Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13
-
2023-509242-35-00
HR+/HER2- early breast cancer 5 2020-07-23
-
2024-515769-32-00
HR+/HER2- early breast cancer 5 2019-07-02
-
2023-509671-17-00
Breast Cancer 5 2017-07-12
-
2023-508472-11-00
Patients with early breast cancer 5 2018-06-13
-
2024-518022-33-00
Advanced Stage of Hodgkin Lymphoma 5 2016-07-15